Compare Charles River Laboratories Intl. Inc (CRL) vs Eaton Corporation plc (ETN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Eaton Corporation plc — how do they compare? Charles River Laboratories Intl. Inc trades at $229.77 (market cap $11.14B), while Eaton Corporation plc trades at $411.54 (market cap $161.35B). The key difference: Eaton Corporation plc is far larger — about 14.5× Charles River Laboratories Intl. Inc's market cap, and Eaton Corporation plc pays a 1.06% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | ETN | |
|---|---|---|
Market Cap | $11.14B | $161.35B |
Sector | Health | Technology |
52-Week High | $233.60 | $435.78 |
52-Week Low | $145.57 | $315.82 |
Enterprise Value | $14.00B | $182.43B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Eaton Corporation (ETN) trades at $402.85, down 1.09% on the day, with a bearish technical signal from moving averages. The stock exhibits strong fundamentals, including a 13.99% net income margin and consistent quarterly earnings beats, most recently in Q1 2026. Recent news highlights growth in data center and aerospace markets, supported by strategic acquisitions and a $2.1 billion R&D investment in 2025.
The outlook remains positive, driven by robust analyst sentiment with a $449.50 consensus price target and no sell ratings. Key opportunities include exposure to high-growth infrastructure and AI-related power demand. Risks involve elevated valuation multiples, such as a P/E of 40.66, and potential execution challenges from recent investments, with Q2 2026 earnings on July 31, 2026, serving as a near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
